Spero Therapeutics (SPRO) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares.
View SPRO analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year price objectives for Spero Therapeutics' stock. Their SPRO share price forecasts range from $7.00 to $8.00. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 509.8% from the stock's current price.
View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts.

Spero Therapeutics' stock was trading at $1.73 on January 1st, 2023. Since then, SPRO shares have decreased by 28.9% and is now trading at $1.23.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our SPRO earnings forecast.

Spero Therapeutics, Inc. (NASDAQ:SPRO) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.06. The company had revenue of $2.72 million for the quarter, compared to the consensus estimate of $2.20 million. Spero Therapeutics had a negative net margin of 18.59% and a negative trailing twelve-month return on equity of 17.69%.

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

(SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Spero Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Anson Funds Management LP (6.54%), Atlas Venture Life Science Advisors LLC (1.93%), Renaissance Technologies LLC (1.13%), BlackRock Inc. (1.00%), Geode Capital Management LLC (0.74%) and AWM Investment Company Inc. (0.73%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin, Kamal Hamed, Sath Shukla and Timothy Keutzer.
View institutional ownership trends.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SPRO stock can currently be purchased for approximately $1.23.

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $64.85 million and generates $53.51 million in revenue each year. The company earns $-46,420,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis.

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.